Clinical Trials Browser

Anemia, Blast Crisis, Burkitt Lymphoma, Graft vs Host Disease, Hodgkin Disease, Leukemia, Leukemia, Megakaryoblastic, Acute, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT00211211 2017-12-08

FREE Study - Fracture Reduction Evaluation

Phase 4 Completed

300 enrolled

Plasma cellSarcoma

Back Pain, Bone Diseases, Metabolic, Bone Neoplasms, Multiple Myeloma, Osteoporosis

NCT02268890 2016-07-11

A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma

Phase 4 Completed

18 enrolled

Plasma cell

Multiple Myeloma

NCT00242528 2015-04-14

Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.

Phase 4 Withdrawn

Plasma cell

Multiple Myeloma

NCT00352703 2014-11-03

PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

Phase 4 Completed

145 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Stomatitis

NCT01868828 2013-06-06

A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma

Phase 4 Unknown

50 enrolled

Plasma cell

Multiple Myeloma

NCT00029224 2012-02-01

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

Phase 4 Completed

500 enrolled

BreastGenitourinaryPlasma cell

Breast Neoplasms, Multiple Myeloma, Pain, Prostatic Neoplasms

NCT00104104 2011-06-29

A Multiple Myeloma Trial in Patients With Bone Metastases

Phase 4 Completed

179 enrolled 15 charts

Plasma cell

Multiple Myeloma

NCT01249690 2010-11-30

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

Phase 4 Unknown

100 enrolled

Plasma cell

Multiple Myeloma

NCT00257114 2008-02-11

Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability

Phase 4 Completed

Plasma cell

Multiple Myeloma

Clinical Trials

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

BLOOD-dose

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

MagnetisMM15

Isa-VRD in TIE HRMM

CHUQUL_HO001

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Plan Development for Giving Teclistamab in the Outpatient Setting

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

VRd MM Fibrate

SCILLA

Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

POMAlternative

BE-Dasatinib

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients

Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation

IFM-01-04

A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation

Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

Magnolia

Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

US MM-7

Z-MARK

AZABACHE

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

PDD vs PAD to Treat Initially Diagnosed MM

Velcadito

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

FREE Study - Fracture Reduction Evaluation

A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma

Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.

PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

A Multiple Myeloma Trial in Patients With Bone Metastases

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability